No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
FULC240816C10000
- 0.65
- +0.10+18.18%
15min DelayClose Jul 23 15:59 ET
0.70High0.65Low
0.65Open0.55Pre Close235 Volume110 Open Interest10.00Strike Price15.63KTurnover117.95%IV20.48%PremiumAug 16, 2024Expiry Date0.00Intrinsic Value100Multiplier23DDays to Expiry0.65Extrinsic Value100Contract SizeAmericanOptions Type0.4023Delta0.1453Gamma13.60Leverage Ratio-0.0222Theta0.0019Rho5.47Eff Leverage0.0087Vega
Intraday
- 5D
- Daily
News
Piper Sandler Maintains Fulcrum Therapeutics(FULC.US) With Buy Rating, Raises Target Price to $16
Fulcrum Therapeutics (FULC) Receives a Buy From Piper Sandler
Census Acquires Fulcrum to Enhance Data Collaboration and Modeling
Top 3 Health Care Stocks That Should Keep You Up At Night This Quarter
Is Fulcrum Therapeutics (NASDAQ:FULC) In A Good Position To Deliver On Growth Plans?
Fulcrum Therapeutics (NASDAQ:FULC) Delivers Shareholders Stellar 110% Return Over 1 Year, Surging 27% in the Last Week Alone
Comments
$Fulcrum Therapeutics(FULC.US$ Its lead candidate, Losmapimod, is a selective p38α/β mitogen-activated protein kinase inhibitor. It is a potentially transformative treatment for FSHD, a rare and debilitating disease for which no approved treatments exist. The FDA has since granted Losmapimod Fast Track designation and Orphan Drug Designation for treating this condition. It is undergoing a Phase 3 study, and Fulcrum expects to report topline data in the fourth quarter of 2024.
1
2
$Fulcrum Therapeutics(FULC.US$ Oh come on what are you waiting for we all know we goin up
$Fulcrum Therapeutics(FULC.US$ Long term looking for dollar 15 range, possible 17 price target to hit. 13.7 resistance 10.4 Fulcrum
5
$Fulcrum Therapeutics(FULC.US$ Fulcrum Therapeutics Inc: Fulcrum Will Receive an Upfront Payment of $80.0 Mln
1
4
Read more
JESSE JAMES8832 : might be something
TrytosaveabitOP JESSE JAMES8832: Yup! I will be looking to see where it starts to consolidate over the next couple weeks. Then start scaling in!